• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

    2/24/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email

    A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System

    MENLO PARK, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced that multiple presentations on the OMNI® Surgical System ("OMNI") will be presented at the 2025 American Glaucoma Society ("AGS") Annual Meeting in Washington, D.C. from February 26 to March 1. These presentations will showcase new data on the clinical effectiveness and safety of OMNI across diverse patient populations.

    The data reinforces the safety and clinical effectiveness of OMNI in treating primary open-angle glaucoma in adult patients. Several of the presentations will feature data curated by Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD). The data stems from a partnership between Verana Health and the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), which is one of the largest specialty society clinical data registries in all of medicine and the first comprehensive eye disease clinical registry in the United States.

    "This new data from the IRIS Registry provides valuable real-world insights into the performance of OMNI across diverse patient populations and disease severities," said Leon W. Herndon Jr., MD, Duke University. "For example, our study showed that MIGS, including OMNI, when combined with cataract surgery in Black patients, resulted in clinically and statistically significant reductions in IOP through 24 months as well as statistically significant reductions in medication through 36 months."

    Results of a systematic literature review and meta-analysis of clinical, economic, and humanistic evidence of the OMNI Surgical System and its predecessors for the treatment of open-angle glaucoma ("OAG") will also be presented.

    "Our review and analysis highlighted the accumulation of data demonstrating the favorable efficacy and safety profiles of OMNI and its predecessors over periods up to 36 months," said Sameh Mosaed, MD, Professor and Chief of Glaucoma Division at the Gavin Herbert Eye Institute of the University of California, Irvine. "These results position OMNI as a beneficial long-term treatment option for patients with OAG."

    "The breadth of clinical data presented at AGS highlights the long-term safety and effectiveness of OMNI in a wide range of glaucoma patients, including diverse patient populations as well as patients with different disease severities," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "These new findings reflect our commitment to advancing glaucoma care and providing physicians with effective treatment options that ultimately benefit patients by reducing their dependence on medications and improving their quality of life."

    Launched in 2014, the IRIS Registry has amassed over 851 million patient encounters and 80 million unique de-identified patients from more than 30 electronic health records ("EHRs") and 15,000 ophthalmologists and other eye care professionals across the U.S.

    OMNI enables an implant-free, ab interno minimally invasive glaucoma surgery ("MIGS") procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with glaucoma.

    Presentations featuring OMNI data at AGS include:

    • Thursday, February 27, 8:00 AM – 9:00 AM EST: 
      • Systematic Review and Meta-analysis of Clinical, Economic, and Humanistic Evidence for the Canaloplasty/Trabeculotomy Surgical System (CTSS) in Open-Angle Glaucoma Treatment
      • Presenting author: Sameh Mosaed, MD, UC Irvine

        Location: Ambassador Room – This meta-analysis of 22 unique studies, including 2,379 eyes, concluded that OMNI and predecessor devices (CTSS) consistently reduced intraocular pressure ("IOP") and decreased the need for medication up to 36 months. The data also showed that both standalone and combined treatment effectively reduced IOP and medication use for up to 24 months.



    • Thursday, February 27, 5:11 PM – 5:19 PM EST: 
      • What's your sign? GEMINI 
      • Presenting author: Mona Kaleem, MD, Johns Hopkins School of Medicine

        Location: Regency Ballroom – We are pleased that AGS has recognized our prospective GEMINI study as a landmark trial in glaucoma. This presentation is part of the Surgery Day Section 5: AGS/ASCRS Symposium "From Sea to Shining Sea" - Landmark Trials in the MIGS Revolution



    • Friday, February 28, 8:00 AM – 9:00 AM EST:
      • Standalone Canaloplasty and Trabeculotomy Outcomes for Phakic and Pseudophakic Eyes: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Analysis
      • Presenting author: Mark Pyfer, MD, Northern Ophthalmic Associates

        Location: Ambassador Room – This study demonstrated that OMNI provided clinically and statistically significant IOP reductions in both phakic and pseudophakic eyes, with an increase in medication-free patients at 36 months.
      • Ab Interno Minimally Invasive Glaucoma Surgery Effectiveness in Black Patients: IRIS® Registry Study
      • Presenting author: Leon W. Herndon Jr., MD, Duke University

        Location: Ambassador Room – This study showed that MIGS procedures, including OMNI, combined with cataract surgery in Black patients, resulted in significant reductions in IOP and medication use.
      • 36-Month Outcomes from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight): Standalone Canaloplasty and Trabeculotomy in Eyes with Mild, Moderate, and Severe Primary Open-Angle Glaucoma (POAG)
      • Presenting author: Christine Funke, MD, Barnet Dulaney Perkin Eye Center

        Location: Ambassador Room – This study demonstrated clinically and statistically significant IOP reductions across all glaucoma severity levels (mild, moderate, and severe) following standalone canaloplasty and trabeculotomy using the OMNI Surgical System.

    Additionally, Sight Sciences will host a lunch symposium where leading experts will explore a pivotal question: Will You Wait or Act? The Crucial Choice in Combating Glaucoma with Interventional Treatment.

    • Date and Time: 
      • Saturday, March 1, 2025
      • 1:00 PM – 2:15 PM EST
    • Location: 
      • AGS Diamond Theater
    • Faculty: 
      • Ike Ahmed, MD; John A. Moran Eye Center, Salt Lake City, UT
      • Reay H. Brown, MD; Atlanta Ophthalmology Associates, Atlanta, GA
      • Christine M. Funke, MD; Barnet Dulaney Perkins, Phoenix, AZ
      • Zarmeena Vendal, MD; Westlake Eye Specialists, Austin, TX

    To register or explore other Sight Sciences events at AGS, visit www.sightsciences.com/ags.

    For hands-on demos and more events and information, stop by booth #48 during exhibit hours.

    About Sight Sciences

    Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction ("MGD") when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.

    The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. Visit www.omnisurgical.com/ifu to access the instructions for use, warnings, precautions, and adverse event information.

    About Verana Health

    Verana Health® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in ophthalmology, urology, and neurology, Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.

    Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. IRIS is a registered trademark of the American Academy of Ophthalmology. Verana Health is a registered trademark of Verana Health.

    Forward-Looking Statements

    This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, without limitation statements regarding presentation of new real-world data on OMNI's clinical effectiveness and safety across diverse patient populations, anticipated presentation of clinical data and studies at AGS, and positioning of OMNI as a beneficial long-term treatment option for patients with OAG. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    © 2025 Sight Sciences. All rights reserved.

    Media contact: 

    [email protected]

    Investor contact: 

    Philip Taylor

    Gilmartin Group

    415.937.5406

    [email protected]



    Primary Logo

    Get the next $SGHT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    7/10/2023$15.00 → $9.00Buy → Neutral
    Citigroup
    More analyst ratings

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      11/14/24 11:57:36 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      2/14/24 5:24:02 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sight Sciences Inc.

      SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

      2/13/24 6:52:37 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. was granted 12,767 shares, increasing direct ownership by 8% to 167,767 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:39:13 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bauerlein Alison sold $45,430 worth of shares (13,066 units at $3.48), decreasing direct ownership by 2% to 636,728 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:38:03 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $53,250 worth of shares (20,000 units at $2.66) and was granted 24,000 shares, increasing direct ownership by 40% to 155,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      3/13/25 9:51:29 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $19,250 worth of shares (5,000 units at $3.85), increasing direct ownership by 5% to 111,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      12/9/24 6:16:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

      MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences' management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company's website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecar

      5/14/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Sight Sciences with a new price target

      UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

      12/6/24 8:14:13 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences downgraded by Lake Street with a new price target

      Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously

      11/4/24 8:26:06 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Sight Sciences with a new price target

      Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00

      8/21/24 8:27:48 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Financials

    Live finance-specific insights

    See more
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

      MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg

      3/5/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    SEC Filings

    See more
    • SEC Form SD filed by Sight Sciences Inc.

      SD - Sight Sciences, Inc. (0001531177) (Filer)

      5/30/25 4:35:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Sight Sciences Inc.

      10-Q - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:16:05 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:08:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Gary Burbach to its Board of Directors

      MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

      4/22/25 4:05:00 PM ET
      $BWXT
      $SGHT
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sight Sciences Appoints Matt Link as Chief Commercial Officer

      MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth

      9/11/23 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care